MaxCyte, Inc.

NasdaqGS:MXCT Stock Report

Market Cap: US$87.5m

MaxCyte Management

Management criteria checks 3/4

MaxCyte's CEO is Maher Masoud, appointed in Jan 2024, has a tenure of 2.33 years. total yearly compensation is $2.69M, comprised of 22% salary and 78% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $142.96K. The average tenure of the management team and the board of directors is 2.3 years and 4.2 years respectively.

Key information

Maher Masoud

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage21.95%
CEO tenure2.3yrs
CEO ownership0.2%
Management average tenure2.3yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

Seeking Alpha • Mar 15

MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price

Summary MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. The company's core revenue is increasing and growth strategies have good prospects, driven by the strong growth of the global cell therapy market. Geopolitical tensions and a slowdown in the economy have hurt the share price, not problems in the company's business operations. MaxCyte's robust financial situation and strategic growth initiatives make its current share price attractive relative to its potential upside. Read the full article on Seeking Alpha
Seeking Alpha • Sep 21

MaxCyte expands capacity by relocating to new HQ in Maryland

MaxCyte (NASDAQ:MXCT) said it relocated its headquarters to Key West Avenue in Rockville, Maryland, within Maryland's I-270 Biotech Corridor. The new 67K square-foot facility increases MaxCyte's in-house manufacturing capacity and research and process development lab space, the company said in a Sept. 21 press release. MXCT -2.09% to 6.10 premarket Sept. 21
Seeking Alpha • Jul 12

MaxCyte signs strategic platform with LG Chem

MaxCyte (NASDAQ:MXCT) has announced the signing of a strategic platform license with LG Chem, aiming to create new value for its customers based on science. Under the terms, LG Chem obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue. “This partnership represents our first SPL with a South Korean company and broadens our reach into Asia to provide advanced technologies that support the clinical and commercial development of engineered cell therapies, and ultimately change the lives of patients with cancer.” said Doug Doerfler, President and CEO of MaxCyte.
Seeking Alpha • Sep 06

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100% gross margins) are set to account for a larger percentage of revenues over time. MXCT offers an attractive risk/return profile for investors that want exposure to the cell and gene therapy area, but do not have the risk appetite to invest directly in the space.

CEO Compensation Analysis

How has Maher Masoud's remuneration changed compared to MaxCyte's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$3mUS$590k

-US$45m

Sep 30 2025n/an/a

-US$46m

Jun 30 2025n/an/a

-US$45m

Mar 31 2025n/an/a

-US$42m

Dec 31 2024US$4mUS$590k

-US$41m

Sep 30 2024n/an/a

-US$36m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$890kUS$450k

-US$38m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$791kUS$413k

-US$24m

Compensation vs Market: Maher's total compensation ($USD2.69M) is above average for companies of similar size in the US market ($USD622.91K).

Compensation vs Earnings: Maher's compensation has been consistent with company performance over the past year.

CEO

Maher Masoud (49 yo)

2.3yrs
Tenure
US$2,687,657
Compensation

Mr. Maher Masoud is President, CEO & Executive Director of MaxCyte, Inc. since January 1, 2024 and served as its Head of Global Business Development and Legal Officer since November 2023 and had been its S...

Leadership Team

NamePositionTenureCompensationOwnership
Maher Masoud
President2.3yrsUS$2.69m0.16%
$ 143.0k
Parmeet Ahuja
Chief Financial Officerless than a yearno datano data
Jay Gelfman
Chief Operations Officer2.3yrsno datano data
Jack Horgan
Senior Vice President of Corporate Development2.6yrsno datano data
Ana-Paula Fernandes
Senior Vice President of Global Sales1.3yrsno datano data
Jill Mayer
Senior Vice President of Human Resources2.3yrsno datano data
2.3yrs
Average Tenure

Experienced Management: MXCT's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Maher Masoud
President2.3yrsUS$2.69m0.16%
$ 143.0k
William Brooke
Independent Non-Executive Director22.2yrsUS$186.82k0.11%
$ 99.4k
Patrick Balthrop
Independent Non-Executive Director3.5yrsUS$169.32k0.020%
$ 17.5k
Richard Douglas
Independent Non-Executive Chairman of the Board8.3yrsUS$204.32k0.19%
$ 164.5k
Stanley Erck
Independent Non-Executive Director21.2yrsUS$176.82k0.34%
$ 301.5k
John Johnston
Independent Non-Executive Director10.3yrsUS$169.32k0.13%
$ 116.0k
Yasir Al-Wakeel
Independent Non-Executive Director4.9yrsUS$169.32k0.020%
$ 17.5k
Rekha Hemrajani
Independent Non-Executive Director4.9yrsUS$179.32k0.010%
$ 8.7k
Marcela Maus
Member of Scientific Advisory Board3.2yrsno datano data
Cenk Sumen
Member of Scientific Advisory Board2.3yrsUS$897.25kno data
Oliver Rando
Member of Scientific Advisory Board3.2yrsno datano data
Avery Posey
Member of Scientific Advisory Board3.2yrsno datano data
4.2yrs
Average Tenure
60.5yo
Average Age

Experienced Board: MXCT's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/12 21:49
End of Day Share Price 2026/05/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MaxCyte, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Matthew HewittCraig-Hallum Capital Group LLC
Julie SimmondsPanmure Liberum